TGFB1 and systemic sclerosis: demonstrated that in SSc the inhibition of CD38 may boosts NAD+ levels, which in turn increases sirtuin (SIRT) activation and, at last, induces the downregulation of TGFβ-SMAD pathway, which is strongly implicated in SSc pathogenesis (28, 31, 32).